Marstacimab ELISA Kit (KDC82803)

Colorimetric

Plasma, Serum

Quantitative

0.31-5 μg/mL

0.156 μg/ml

CV<20%

80-120%

2-8 ℃

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Marstacimab, previously known as PF-06741086, is a fully human monoclonal antibody IgG1 antibody that binds to the K2 domain of TFPI at nanomolar to suprananomolar concentration ranges. Non-clinical experiments demonstrated that marstacimab could enhance thrombin generation in vitro and in vivo in a concentration-dependent manner. In vitro thrombin generation assays (TGAs) and dilute prothrombin time (dPT) assays evaluating Marstacimab added to donor plasma from healthy normal volunteers and patients with haemophilia A, haemophilia B, and haemophilia A with inhibitors have all shown the ability of marstacimab to increase coagulation activity and promote haemostasis. Bleed control was demonstrated in severe injury mice models of haemophilia A and B.